Last reviewed · How we verify
CKD-352
CKD-352 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
CKD-352 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | CKD-352 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CKD-352 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism is distinct from selective estrogen receptor modulators (SERMs) and provides more complete suppression of estrogen receptor activity in hormone receptor-positive breast cancer cells.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Vaginal dryness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |